Duvelisib (IPI-145), an oral dual inhibitor of PI3K-delta,gamma, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia Meeting Abstract
| Authors: | O'Brien, S.; Patel, M.; Kahl, B.; Horwitz, S.; Foss, F.; Porcu, P.; McLaughlin, J.; Sweeney, J.; Allen, K.; Faia, K.; Stern, H.; Flinn, I. |
| Abstract Title: | Duvelisib (IPI-145), an oral dual inhibitor of PI3K-delta,gamma, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia |
| Meeting Title: | XVI International Workshop on Chronic Lymphocytic Leukemia |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 56 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2015 Sep 6-9 |
| Meeting Location: | Sydney, Australia |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2015-09-01 |
| Start Page: | 103 |
| Language: | English |
| ACCESSION: | WOS:000368710200123 |
| PROVIDER: | wos |
| DOI: | 10.3109/10428194.2015.1080893 |
| Notes: | Meeting Abstract: 122 -- Source: Wos |
